Key result
Escherichia coli LPS dose-dependently and time-dependently (10-60 min) inhibited platelet aggregation in human and rabbit platelets via a nitric oxide/cyclic GMP pathway.
Answers are grounded in this paper and cite their sources.
E. coli LPS inhibits platelet aggregation via a nitric oxide/cyclic GMP pathway, which may contribute to bleeding diathesis in sepsis.
In this study, Escherichia coli LPS dose-dependently (100-500 microg/ml) and time-dependently (10-60 min) inhibited platelet aggregation in human and rabbit platelets stimulated by agonists. LPS also dose-dependently inhibited the intracellular Ca2+ mobilization in human platelets stimulated by collagen. In addition, LPS (200 and 500 microg/ml) significantly increased the formation of cyclic GMP but not cyclic AMP in platelets. LPS (200 microg/ml) significantly increased the production of nitrate within a 10-min incubation period. Furthermore, LPS also dose-dependently inhibited platelet aggregation induced by PDBu (30 nmol/l), a protein kinase C activator. These results indicate that the antiplatelet activity of E. coli LPS may be involved in the activation of a nitric oxide/cyclic GMP pathway in platelets, resulting in inhibition of platelet aggregation. Therefore, LPS-mediated alteration of platelet function may contribute to bleeding diathesis in septicemic and endotoxemic patients.
No takes yet. Share an insight, caveat, or question.
Sheu et al. (1999) studied this question. Escherichia coli lipopolysaccharide (LPS) was evaluated on platelet aggregation. Escherichia coli LPS dose-dependently and time-dependently (10-60 min) inhibited platelet aggregation in human and rabbit platelets via a nitric oxide/cyclic GMP pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: